Published • loading... • Updated
[Opinion] Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colore
This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS), and a significant overall survival (OS) benefit, reducing the risk of death by […] The post Pierre Fabre Laboratories receives CHMP positive…
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
